Mirati Therapeutics Stories Back to Perspectives Stories Share Tweet Email Copy Collaboration KRAS PERSPECTIVES Learn more about KRAS mutations September 13, 2021 Dr. Spira, a director at the Virginia Cancer Specialists Research Institute, Co-Chair of the US Oncology Thoracic Oncology Committee, and a faculty member at Johns Hopkins School of Medicine discusses why KRASG12C is a prolific problem in this Mirati-sponsored episode of the “Cure Talks Cancer” Podcast. Dr. Spira explains the science of the KRAS gene and introduces KRASRegeneration.com, a website for HCPs that builds awareness of the KRASG12C mutation. The conversation focuses on the importance of educating oncologists around the KRAS mutation in lung cancer. Listen here. More Stories Exploiting cancer’s weakness, precisely Read more KRAS Conversations: Providing patients with options Read more Mirati Therapeutics © Copyright 2021 - Mirati Therapeutics, Inc. 858.332.3410 info@mirati.com Terms of Use Privacy Cookies Expanded Access Community Guidelines

Mirati Therapeutics About Us We are a clinical-stage targeted oncology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. Our culture is designed to unleash the potential of our science and our people by creating an environment that fosters open-mindedness and collaboration as we seek to transform the lives of patients with cancer. Unified for patients, our vision is to unlock the science behind the promise of a life beyond cancer. Executive Leadership Our leadership is comprised of experienced and passionate industry veterans who are committed to delivering best-in-class targeted therapies that help improve the lives of cancer patients. Learn more about our executive leadership team Business Development Partnerships and collaborations play an important role in our goal to unlock progress and expand potential to meaningfully impact the treatment of cancer. Learn more about our collaborative partnerships Our Heritage Mirati has been relentlessly focused on translating science into hope for patients over the last decade. Learn more about Mirati’s heritage Mirati Therapeutics © Copyright 2021 - Mirati Therapeutics, Inc. 858.332.3410 info@mirati.com Terms of Use Privacy Cookies Expanded Access Community Guidelines

Mirati Therapeutics Our Heritage 1995 MethylGene, Inc. Established MethylGene, Inc. is established in Canada and listed on the Canadian Exchange. Next 1 2 3 4 5 6 7 8 9 Mirati Therapeutics © Copyright 2021 - Mirati Therapeutics, Inc. 858.332.3410 info@mirati.com Terms of Use Privacy Cookies Expanded Access Community Guidelines